Interestingly, granzyme B-degraded type IV collagen fragments (C4G) associate with favorable anti-CTLA-4 treatment response in metastatic melanoma patients (Jensen et al., 2018; Jensen et al., 2020; St-Pierre and Potworowski, 2000). This evidence concerns the gene GZMB and metastatic melanoma.